Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · IEX Real-Time Price · USD
1.760
-0.140 (-7.37%)
At close: Jul 2, 2024, 4:00 PM
1.750
-0.010 (-0.57%)
After-hours: Jul 2, 2024, 7:42 PM EDT
Company Description
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Regulus Therapeutics Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 4, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Joseph P. Hagan M.B.A. |
Contact Details
Address: 4224 Campus Point Court, Suite 210 San Diego, California 92121 United States | |
| Phone | 858-202-6300 |
| Website | regulusrx.com |
Stock Details
| Ticker Symbol | RGLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505512 |
| CUSIP Number | 75915K309 |
| ISIN Number | US75915K3095 |
| Employer ID | 26-4738379 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph P. Hagan M.B.A. | Chief Executive Officer and Director |
| Crispina Calsada CPA | Chief Financial Officer |
| Christopher Ray Aker J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research and Development and Director |
| Daniel J. Penksa | Vice President of Finance and Controller |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations |
| Dr. Rekha Garg M.D., M.S. | Senior Vice President of Clinical Development and Regulatory |
| Edmund Lee Ph.D. | Vice President of Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | 8-K | Current Report |
| May 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 17, 2024 | 8-K | Current Report |
| May 9, 2024 | 424B5 | Filing |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 30, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2024 | EFFECT | Notice of Effectiveness |
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |